Latest Capital Raises News

Yojee Limited reported a 34% revenue decline to $675k and a 29% reduction in net loss to $6.02 million for FY2025, reflecting a strategic pivot and accelerated development of its MOSAIC freight forwarding platform. The company raised $8.9 million to fund growth and platform commercialization.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

Wellnex Life Limited reported a strong 40% revenue increase in FY25 driven by its Pain Away brand, yet posted a wider loss due to one-off costs and finance expenses. The company’s balance sheet strengthened following a dual AIM listing and debt settlements.

Jcurve Solutions Limited reported a significant turnaround in FY25 with a Normalised EBITDA profit and a narrowed net loss, despite an 11% revenue decline. The company also strengthened its Asia presence through acquisition and boosted liquidity with a $1 million capital raise.

Beonic Ltd reported a significantly reduced net loss of $3.17 million for FY2025, alongside improved margins and EBITDA profitability, underpinned by a major North African airport contract and a $4.18 million convertible note raise to accelerate growth.

BPH Global Limited reported a strong 161.7% revenue increase to nearly $288,000 for FY25, driven by new seaweed operations in Indonesia, yet the company remains in the red with a $1.3 million net loss. The firm continues to raise capital and integrate acquisitions as it charts a path forward.

Eden Innovations Ltd reported a 21% revenue increase driven by global sales growth, yet its net loss widened significantly due to prior year asset revaluations and ongoing operational costs. The company is undertaking major financial restructuring including a share consolidation and rights issue to stabilize its balance sheet.

Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

NoviqTech Limited reported a $1.63 million loss for the half-year ending June 2025, while securing key partnerships and raising over $1 million to fuel its sustainability and blockchain innovation.

Pure Foods Tasmania reported a 30% revenue decline in FY25 but improved its net loss through cost-cutting and product rationalisation. Post-year-end recapitalisation efforts aim to strengthen the balance sheet and support the turnaround.